Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or
“Novo”), and Clinical Consultants International, LLC (“CCI”), a
Novo wholly-owned subsidiary, today announced the signing of a
Consulting Services Agreement (the “Agreement”), with Futura
Surgicare Pvt Ltd (“Futura”), an India-based leading manufacturer
of wound closure and surgical products that are marketed and
distributed in over 70 countries worldwide under the trade name
“Dolphin Sutures”. Futura’s comprehensive and innovative product
offering includes surgical sutures, skin staplers, hernia meshes,
surgical tapes, hemostats, and bone wax.
The Agreement provides for (i) CCI to assist Futura in obtaining
U.S. FDA 510K approvals for its advanced surgical products, and
(ii) CCI and Futura to enter into a strategic partnership to
introduce high-quality Dolphin Sutures and mesh products to the
North American healthcare market, potentially bringing substantial
cost savings and improved care to American patients and healthcare
providers.
Dr. Joseph M. Chalil, MD, MBA, FACHE, President of CCI,
remarked, "We are proud to partner with Futura in bringing Dolphin
Sutures and mesh products to the North American market. FDA
approval of these high-quality products would symbolize a beacon of
hope in addressing the high costs of the American healthcare
market. We are confident this partnership will mark a significant
milestone in offering affordable and superior surgical
solutions."
About Futura Surgicare Pvt
Ltd
Futura Surgicare Pvt Ltd, under the stewardship of
second-generation leader Abhijith Sagar, is pioneering the future
of healthcare with cutting-edge surgical sutures, including
Polyglycolic Acid, Polyglactin 910, PTFE, and Barbed sutures.
Leveraging 30 years of industry leadership from Bangalore, India,
the company is recognized for its firsts in synthetic absorbable
sutures and its globally sourced high-quality materials. Upholding
the highest standards, Futura is accredited with ISO 9001:2008, ISO
13485, CE2460, WHO-GMP, and GLP certifications. Abhijith Sagar
exemplifies the transformative power of education and dedication as
he guides Futura toward new horizons in medical innovation.
About Clinical Consultants
International LLC
Established in 2006 in Michigan as a hospital consulting firm,
today, CCI is a global consulting firm specializing in providing
value-added services for the pharmaceutical, biotech, healthcare
management, hospital management, medical marketing and strategic
planning, health policy, and medical device sectors. Headquartered
in Boca Raton, Florida, we leverage over 30 years of industry
experience and our expert consultants worldwide to support our
clients.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach
to patient-first health and wellness through a multidisciplinary
healthcare ecosystem of services and product innovation. Novo
offers an essential and differentiated solution to deliver or
intends to deliver, these services and products through the
integration of medical technology, advanced therapeutics, and
rehabilitative science.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity, is an
essential solution to the rapidly evolving fundamental
transformation of how non-catastrophic healthcare is delivered now
and in the future. Specific to non-critical care, ongoing
advancements in medical technology and interconnectivity allow for
a shift of the patient/practitioner relationship to the patient’s
home and away from on-site visits to primary medical centers with
mass services. This acceleration of “ease-of-access” in the
patient/practitioner interaction for non-critical care diagnosis
and subsequent treatment minimizes the degradation of non-critical
health conditions to critical conditions and allows for more
cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is
centered on three primary pillars to best support the
transformation of non-catastrophic healthcare delivery to patients
and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary
primary care services through (i) an affiliate network of clinic
facilities, (ii) small and micro footprint-sized clinic facilities
primarily located within the footprint of box-store commercial
enterprises, (iii) clinic facilities operated through a franchise
relationship with the Company, and (iv) corporate operated clinic
facilities.
- Second Pillar: Technology. Develop, deploy, and integrate
sophisticated interconnected technology, interfacing the patient to
the healthcare practitioner, thus expanding the reach and
availability of the Company’s services beyond the traditional
clinic location to geographic areas not readily providing advanced,
peripheral-based healthcare services, including the patient’s
home.
- Third Pillar: Products. Develop and distribute effective,
personalized health and wellness product solutions, allowing for
the customization of patient preventative care remedies and,
ultimately, a healthier population. The Company’s science-first
approach to product innovation further emphasizes our mandate to
create and provide over-the-counter preventative and maintenance
care solutions.
Innovation through science combined with the integration of
sophisticated, secure technology assures Novo Integrated Sciences
of continued cutting-edge advancement in patient-first
platforms.
For more information concerning Novo Integrated Sciences, please
www.novointegrated.com
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts included in
this press release are forward-looking statements. In some cases,
forward-looking statements can be identified by words such as
"believe," “intend,” "expect," "anticipate," "plan," "potential,"
"continue" or similar expressions. Such forward-looking statements
include risks and uncertainties, and there are important factors
that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements. These
factors, risks, and uncertainties are discussed in Novo’s filings
with the Securities and Exchange Commission. Investors should not
place any undue reliance on forward-looking statements since they
involve known and unknown uncertainties and other factors that are,
in some cases, beyond Novo’s control, which could and likely will
materially affect actual results, levels of activity, performance,
or achievements. Any forward-looking statement reflects Novo’s
current views with respect to future events and is subject to these
and other risks, uncertainties, and assumptions relating to
operations, results of operations, growth strategy, and liquidity.
Novo assumes no obligation to update or revise these
forward-looking statements for any reason publicly or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the future. The content of any
website referenced in this press release is not incorporated by
reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221772776/en/
Chris David, COO Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (888) 512-1195
Grafico Azioni Novo Integrated Sciences (NASDAQ:NVOS)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Novo Integrated Sciences (NASDAQ:NVOS)
Storico
Da Nov 2023 a Nov 2024
